Pulmonx (LUNG) Competitors

Pulmonx (NASDAQ:LUNG) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.

Do insiders and institutionals have more ownership in LUNG or AXGN?

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by company insiders. Comparatively, 7.0% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is LUNG or AXGN more profitable?

AxoGen has a net margin of -7.91% compared to Pulmonx's net margin of -67.31%. AxoGen's return on equity of -14.91% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-67.31%	-55.36%	-33.53%
AxoGen	-7.91%	-14.91%	-7.49%

Which has more risk and volatility, LUNG or AXGN?

Pulmonx has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Does the MarketBeat Community prefer LUNG or AXGN?

AxoGen received 421 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 72.89% of users gave AxoGen an outperform vote while only 45.57% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 36 45.57%	Underperform Votes 43 54.43%
AxoGen	Outperform Votes 457 72.89%	Underperform Votes 170 27.11%

Do analysts recommend LUNG or AXGN?

Pulmonx currently has a consensus target price of $12.75, suggesting a potential upside of 163.98%. AxoGen has a consensus target price of $22.60, suggesting a potential upside of 38.91%. Given Pulmonx's higher possible upside, equities analysts clearly believe Pulmonx is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
AxoGen	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable earnings & valuation, LUNG or AXGN?

AxoGen has higher revenue and earnings than Pulmonx. AxoGen is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$83.79M	2.32	-$60.84M	-$1.44	-3.35
AxoGen	$187.34M	3.85	-$21.72M	-$0.22	-73.95

Does the media favor LUNG or AXGN?

In the previous week, Pulmonx had 4 more articles in the media than AxoGen. MarketBeat recorded 12 mentions for Pulmonx and 8 mentions for AxoGen. AxoGen's average media sentiment score of 1.33 beat Pulmonx's score of 0.90 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AxoGen beats Pulmonx on 13 of the 18 factors compared between the two stocks.